MediWound's EscharEx Shows Safe, Effective, Rapid Debridement Of Leg Ulcers

MediWound Ltd  (NASDAQ: MDWD ) announced results  from its Phase 2 pharmacology study of EscharEx for the debridement of lower leg ulcers. 70% of patients achieved complete debridement during treatment within up to 8 applications. On average, complete debridement was achieved after 3.9 applications of EscharEx.  Additionally, ... Full story available on